http://orcid.org/0000-0001-8862-9468
References
- World Health Organization [Internet]. Diabetes fact sheet; 2018. [cited 2019 Jul 15]. Available from: www.who.int/news-room/fact-sheets/detail/diabetes.
- World Health Organization [Internet]. Global report on diabetes; 2016. [cited 2020 Jan 15]. Available from: www.who.int/news-room/fact-sheets/detail/diabetes.
- Japan Diabetes Society [Internet]. Treatment guide for diabetes, 2016–2017. Tokyo, Japan: Bunkodo; 2017. [cited 2019 Jun 14]. Available from: http://www.fa.kyorin.co.jp/jds/uploads/Treatment_Guide_for_Diabetes_2016-2017.pdf.
- Eli Lilly Japan K.K., Kobe, Japan. Trulicity Ateos package insert Ver. 1. Revised May 2019. [cited 2020 March 12]. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/530471_2499416G1029_1_12. (Japanese).
- Matfin G, Van Brunt K, Zimmermann AG, et al. Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naïve patients with type 2 diabetes. J Diabetes Sci Technol. 2015;9(5):1071–1079.
- Asakura T. The association between injection device and injection training time of insulin initial self-injection training. Prog Med. 2003;23:3381–3385. (Japanese).
- Yamada KC, Aoki K. Evaluation of usability of insulin self-injection devices. Jpn J Ergonom. 2006;42(2):112–118. (Japanese).
- Glasgow RE, Peeples M, Skovlund SE. Where is the patient in diabetes performance measures? The case for including patient-centered and self-management measures. Diabetes Care. 2008;31(5):1046–1050.
- Asakura T, Suzuki S, Aranishi T, et al. Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch among self-injection-naïve patients with type 2 diabetes mellitus in Japan. Curr Med Res Opin. 2018;34(6):1117–1124.
- American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Suppl 1):S14–S80. [cited 2020 Jan 15]. Available from: https://care.diabetesjournals.org/content/diacare/37/Supplement_1/S14.full.pdf.